Footmender All In One Foot Cream has eight active ingredients that create the following effects: antimicrobial effect that prevents the regrowth of microorganisms for at least 12 hours; an exfoliating effect that removes dead skin cells; footmender binds and retains moisture in the skin; softens the skin; reduces skin sensitivity and slows the release of water; stabilises skin cell renewal; stimulates the healing of cracked skin and strengthens the skin’s barrier effect

Fucibet Cream combines the well-known anti-inflammatory and antipruritic effects of betamethasone with the topical antibacterial action of fusidic acid. Betamethasone valerate is a topical steroid that is rapidly effective in inflammatory dermatoses that normally respond to this form of therapy. More refractory conditions can often be treated successfully. When applied topically, fusidic acid is effective against Staphylococcus aureus, Streptococcus, Corynebacterium, Neisseria and certain clostridia and Bacteroides. Concentrations of 0.03-0.12µg per ml inhibit nearly all strains of S. aureus. The antibacterial activity of fusidic acid is not diminished in the presence of betamethasone

Fucibet Lipid Cream combines the well-known anti-inflammatory and antipruritic effects of betamethasone with the topical antibacterial action of fusidic acid. Betamethasone valerate is a topical steroid that is rapidly effective in inflammatory dermatoses that normally respond to this form of therapy. More refractory conditions can often be treated successfully. When applied topically, fusidic acid is effective against Staphylococcus aureus, Streptococcus, Corynebacterium, Neisseria and certain clostridia and Bacteroides. Concentrations of 0.03-0.12µ per ml inhibit nearly all strains of S. aureus. The antibacterial activity of fusidic acid is not diminished in the presence of betamethasone

Fucidin contains fusidic acid, a potent antibacterial agent. Fusidic acid and its salts show fat and water solubility and strong surface activity, and exhibit an unusual ability to penetrate intact skin. Concentrations of 0.03–0.12mcg fusidic acid per ml inhibit nearly all strains of Staphylococcus aureus. Topical application is also effective against streptococci, corynebacteria, niesseria and certain clostridia

Fucidin H Cream combines the potent topical antibacterial action of fusidic acid with the anti-inflammatory and antipruritic effects of hydrocortisone. Concentrations of 0.03–0.12µg/ml of fusidic acid inhibit nearly all strains of Staphylococcus aureus. Topical application of fusidic acid is also effective against Streptococcus, Corynebacterium, Neisseria and certain clostridia

Full Marks contains isopropyl myristate and cyclomethicone. It is a thin, oily liquid, which spreads quickly and completely through the hair to saturate the scalp and kill head lice and eliminate their eggs. Using the fine-tooth metal comb provided, the solution is then combed through the hair once the required time has elapsed

Combines an antiseptic action of phenol and chlorhexidine digluconate to help prevent infections, plus a soothing local anaesthetic effect of phenol to numb the pain.

A gentle but effective treatment for minor abrasions, wounds, scrapes, burns, bites and stings. The cream contains chlorhexidine dihydrochloride, a mild antiseptic that aids in infection prevention. The cream base softens the skin while also soothing inflammation.

Diabetic foot foam cream formula forms finely meshed “netting” over the skin which not only protects it from harmful external factors, but the skin is able to breathe and its natural functions are retained.

Guselkumab is a human IgG1λ monoclonal antibody (mAb) that binds selectively to the interleukin 23 (IL-23) protein with high specificity and affinity. IL-23, a regulatory cytokine, affects the differentiation, expansion and survival of T cell subsets and innate immune cell subsets, which represent sources of effector cytokines, including IL-17A, IL-17F and IL-22 that drive inflammatory disease. Levels of IL-23 are elevated in the skin of patients with plaque psoriasis. In in vitro models, guselkumab was shown to inhibit the bioactivity of IL-23 by blocking its interaction with cell surface IL-23 receptor, disrupting IL-23-mediated signaling, activation and cytokine cascades. Guselkumab exerts clinical effects in plaque psoriasis through blockade of the IL-23 cytokine pathway.